NRX Pharmaceuticals Files 8-K on Financials
Ticker: NRXPW · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: NRXP
TL;DR
NRXP filed an 8-K on April 2nd detailing its financial condition as of April 1st.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on April 2, 2024, reporting on its results of operations and financial condition as of April 1, 2024. The filing includes financial statements and exhibits related to the company's business.
Why It Matters
This filing provides investors with an update on NRX Pharmaceuticals' financial health and operational results, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate new material events or significant financial changes indicated.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- April 1, 2024 (date) — Earliest event reported
- April 2, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Big Rock Partners Acquisition Corp. (company) — Former company name
FAQ
What specific financial information is detailed in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details are not provided in the provided text.
When was the earliest event reported in this filing?
The earliest event reported is dated April 1, 2024.
What is the filing date of this 8-K report?
The report was filed on April 2, 2024.
What was NRX Pharmaceuticals, Inc. formerly known as?
NRX Pharmaceuticals, Inc. was formerly known as Big Rock Partners Acquisition Corp.
In which state is NRX Pharmaceuticals, Inc. incorporated?
NRX Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-04-02 06:01:03
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Mar
Filing Documents
- nrxp-20240401x8k.htm (8-K) — 42KB
- nrxp-20240401xex99d1.htm (EX-99.1) — 59KB
- nrxp-20240401xex99d1002.jpg (GRAPHIC) — 3KB
- 0001558370-24-004570.txt ( ) — 277KB
- nrxp-20240401.xsd (EX-101.SCH) — 4KB
- nrxp-20240401_def.xml (EX-101.DEF) — 14KB
- nrxp-20240401_lab.xml (EX-101.LAB) — 20KB
- nrxp-20240401_pre.xml (EX-101.PRE) — 15KB
- nrxp-20240401x8k_htm.xml (XML) — 7KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On April 1, 2024, NRx Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth fiscal quarter and year ending December 31, 2023 and provided a business update. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, that is furnished pursuant to this Item 2.02 shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated April 1, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: April 2, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Chief Executive Officer 3